Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares. View ARCT analyst ratings or view top-rated stocks .

What is Arcturus Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. Their ARCT share price targets range from $45.00 to $90.00. On average, they anticipate the company's share price to reach $61.33 in the next twelve months. This suggests a possible upside of 136.1% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts .

How have ARCT shares performed in 2024?

Arcturus Therapeutics' stock was trading at $31.53 at the start of the year. Since then, ARCT shares have decreased by 17.6% and is now trading at $25.98. View the best growth stocks for 2024 here .

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,810,000 shares, an increase of 14.3% from the March 15th total of 4,210,000 shares. Based on an average daily trading volume, of 454,500 shares, the short-interest ratio is presently 10.6 days. Currently, 19.6% of the shares of the company are sold short. View Arcturus Therapeutics' Short Interest .

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ARCT earnings forecast .

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings results on Thursday, March, 7th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($1.69) by $1.37. The biotechnology company had revenue of $33.99 million for the quarter, compared to analysts' expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%.

Is Arcturus Therapeutics a good dividend stock?

Arcturus Therapeutics (NASDAQ:ARCT) pays an annual dividend of $0.71 per share and currently has a dividend yield of 0.00%. Read our dividend analysis for ARCT .

What ETFs hold Arcturus Therapeutics' stock?

ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR) , Subversive Mental Health ETF (SANE) , ARK Genomic Revolution ETF (ARKG) , WisdomTree BioRevolution Fund (WDNA) , Amplify Treatments, Testing and Advancements ETF (GERM) , AXS Green Alpha ETF (NXTE) , Jacob Forward ETF (JFWD) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com . Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO) , Gilead Sciences (GILD) , Novavax (NVAX) , Dynavax Technologies (DVAX) , Pfizer (PFE) , OPKO Health (OPK) , NVIDIA (NVDA) , Abbott Laboratories (ABT) , CRISPR Therapeutics (CRSP) and

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.74%), Hennion & Walsh Asset Management Inc. (0.12%), Allspring Global Investments Holdings LLC (0.11%) and Denali Advisors LLC (0.02%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends .

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ARCT Stock Alerts

$25.98

-0.34 (-1.29%)

(As of 04/19/2024 ET)

Compare

Today's Range: $25.57
▼
$26.88
50-Day Range: $26.32
▼
$42.99
52-Week Range: $17.52
▼
$43.81

Volume: 625,391 shs
Average Volume: 459,719 shs
Market Capitalization: $699.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.33

Get Arcturus Therapeutics alerts:

Arcturus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 136.1% Upside
$61.33 Price Target
Short Interest: Bearish
19.60% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.66
Based on 5 Articles This Week
Insider Trading: Selling Shares
$910,434 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.42) to $5.10 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.15 out of 5 stars

Medical Sector

534th out of 911 stocks

Pharmaceutical Preparations Industry

238th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Arcturus Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
19.60% of the float of Arcturus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Arcturus Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Arcturus Therapeutics has recently increased by 14.25%, indicating that investor sentiment is decreasing significantly.

0.8

Dividend Strength

Dividend Yield
Arcturus Therapeutics does not currently pay a dividend.
Dividend Growth
Arcturus Therapeutics does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Arcturus Therapeutics will have a dividend payout ratio of 14.02% next year. This indicates that Arcturus Therapeutics will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARCT.

2.6

News and Social Media Coverage

News Sentiment
Arcturus Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 11 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $910,434.00 in company stock.
Percentage Held by Insiders
13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($1.42) to $5.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcturus Therapeutics is -24.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcturus Therapeutics is -24.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcturus Therapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARCT Stock News Headlines

March 28, 2024 | insidertrades.com

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $610,573.70 in Stock

March 22, 2024 | insidertrades.com

Insider Selling: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells 8,565 Shares of Stock

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 19, 2024 | americanbankingnews.com

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Buy" from Brokerages

April 16, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)

April 9, 2024 | markets.businessinsider.com

Alnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic Partnerships

April 6, 2024 | cnn.com

Arcturus Therapeutics Holdings, Inc.

April 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 29, 2024 | finanznachrichten.de

Intravacc B.V.: Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

March 28, 2024 | finance.yahoo.com

Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares

March 27, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan

March 22, 2024 | finance.yahoo.com

Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...

March 17, 2024 | finance.yahoo.com

Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 16, 2024 | ca.finance.yahoo.com

ARCT Apr 2024 30.000 call

March 11, 2024 | markets.businessinsider.com

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts

March 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)

March 9, 2024 | seekingalpha.com

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript

March 8, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)

March 8, 2024 | finance.yahoo.com

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript

March 8, 2024 | finance.yahoo.com

Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call

March 8, 2024 | finance.yahoo.com

Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments

March 7, 2024 | investorplace.com

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023

March 7, 2024 | benzinga.com

Recap: Arcturus Therapeutics Q4 Earnings

March 7, 2024 | businesswire.com

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

March 7, 2024 | finance.yahoo.com

ARCT Sep 2024 30.000 put

March 6, 2024 | benzinga.com

Earnings Preview: Arcturus Therapeutics

See More Headlines

Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARCT
CUSIP: N/A
CIK: 1410997
Web: www.arcturusrx.com
Phone: (858) 900-2660
Fax: N/A
Employees: 180
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $61.33
High Stock Price Target: $90.00
Low Stock Price Target: $45.00
Potential Upside/Downside: +133.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,730,000.00
Net Margins: -15.65%
Pretax Margin: -16.72%
Return on Equity: -18.22%
Return on Assets: -11.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.72
Quick Ratio: 4.72

Sales & Book Value

Annual Sales: $169.93 million
Price / Sales: 4.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.42 per share
Price / Book: 2.53

Miscellaneous

Outstanding Shares: 26,920,000
Free Float: 23,201,000
Market Cap: $708.53 million
Optionable: Optionable
Beta: 2.60

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Joseph E. Payne M.Sc. (Age 52)
Founder, President, CEO & Director
Comp: $1.13M
Dr. Padmanabh Chivukula Ph.D. (Age 45)
Founder, Chief Scientific Officer, COO & Secretary
Comp: $787.5k
Mr. Andrew H. Sassine MBA (Age 60)
CFO & Director
Comp: $826.88k
Ms. Neda Safarzadeh
Vice President and Head of IR/PR & Marketing
Mr. Lance Kurata
Chief Legal Officer
Ms. Natash O. Bowman
Chief Human Resources Officer
Mr. Kevin T. Skol
Chief Business Officer
Dr. Juergen Froehlich FCPh (Age 68)
M.D., MBA, Chief Medical Officer
Dr. Igor Smolenov M.D.
Ph.D., Chief Development Officer
Joseph Roberts
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings or view top-rated stocks.
What is Arcturus Therapeutics' stock price target for 2024?: 7 Wall Street analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. Their ARCT share price targets range from $45.00 to $90.00. On average, they anticipate the company's share price to reach $61.33 in the next twelve months. This suggests a possible upside of 136.1% from the stock's current price.
View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts.
How have ARCT shares performed in 2024?: Arcturus Therapeutics' stock was trading at $31.53 at the start of the year. Since then, ARCT shares have decreased by 17.6% and is now trading at $25.98.
View the best growth stocks for 2024 here.
Are investors shorting Arcturus Therapeutics?: Arcturus Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,810,000 shares, an increase of 14.3% from the March 15th total of 4,210,000 shares. Based on an average daily trading volume, of 454,500 shares, the short-interest ratio is presently 10.6 days. Currently, 19.6% of the shares of the company are sold short.
View Arcturus Therapeutics' Short Interest.
When is Arcturus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARCT earnings forecast.
How were Arcturus Therapeutics' earnings last quarter?: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings results on Thursday, March, 7th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($1.69) by $1.37. The biotechnology company had revenue of $33.99 million for the quarter, compared to analysts' expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%.

Is Arcturus Therapeutics a good dividend stock?: Arcturus Therapeutics (NASDAQ:ARCT) pays an annual dividend of $0.71 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for ARCT.
What ETFs hold Arcturus Therapeutics' stock?: ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), WisdomTree BioRevolution Fund (WDNA), Amplify Treatments, Testing and Advancements ETF (GERM), AXS Green Alpha ETF (NXTE), Jacob Forward ETF (JFWD) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?: 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.
What other stocks do shareholders of Arcturus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and
Who are Arcturus Therapeutics' major shareholders?: Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.74%), Hennion & Walsh Asset Management Inc. (0.12%), Allspring Global Investments Holdings LLC (0.11%) and Denali Advisors LLC (0.02%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends.
How do I buy shares of Arcturus Therapeutics?: Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARCT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Arcturus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

ARCT Stock Price History

ARCT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ARCT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™